Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, Toda T, Wada K, Nagai Y.

Neurotherapeutics. 2013 Jul;10(3):440-6. doi: 10.1007/s13311-013-0184-7. Review.

2.

[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].

Nagai Y.

Rinsho Shinkeigaku. 2009 Nov;49(11):913-6. Review. Japanese.

PMID:
20030247
3.

The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.

Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, Takeuchi T, Toda T, Wada K, Nagai Y.

J Amino Acids. 2011;2011:265084. doi: 10.4061/2011/265084. Epub 2011 Jun 30.

4.

Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.

Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, Yamaguchi M, Strittmatter WJ, Burke JR, Toda T.

Hum Mol Genet. 2003 Jun 1;12(11):1253-9.

PMID:
12761040
5.

[Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].

Nagai Y, Nukina N.

Rinsho Shinkeigaku. 2011 Nov;51(11):1108-10. Japanese.

PMID:
22277499
6.

Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.

Popiel HA, Nagai Y, Fujikake N, Toda T.

Neurosci Lett. 2009 Jan 9;449(2):87-92. doi: 10.1016/j.neulet.2008.06.015. Epub 2008 Jun 10.

PMID:
18603372
7.
8.

Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.

Okamoto Y, Nagai Y, Fujikake N, Akiko Popiel H, Yoshioka T, Toda T, Inui T.

Biochem Biophys Res Commun. 2009 Jan 16;378(3):634-9. doi: 10.1016/j.bbrc.2008.11.094. Epub 2008 Dec 4.

PMID:
19061859
10.

Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.

Nagai Y, Fujikake N, Popiel HA, Wada K.

Curr Pharm Biotechnol. 2010 Feb;11(2):188-97. Review.

PMID:
20166962
11.

Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.

Popiel HA, Takeuchi T, Fujita H, Yamamoto K, Ito C, Yamane H, Muramatsu S, Toda T, Wada K, Nagai Y.

PLoS One. 2012;7(11):e51069. doi: 10.1371/journal.pone.0051069. Epub 2012 Nov 30.

12.

A toxic monomeric conformer of the polyglutamine protein.

Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, Urade Y, Goto Y, Naiki H, Toda T.

Nat Struct Mol Biol. 2007 Apr;14(4):332-40. Epub 2007 Mar 18.

PMID:
17369839
13.

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening.

Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR.

J Biol Chem. 2000 Apr 7;275(14):10437-42.

14.

Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.

Saunders HM, Bottomley SP.

Protein Eng Des Sel. 2009 Aug;22(8):447-51. doi: 10.1093/protein/gzp033. Epub 2009 Jul 9. Review.

PMID:
19589877
15.

NMR spectroscopy reveals a preferred conformation with a defined hydrophobic cluster for polyglutamine binding peptide 1.

Ramos-Martín F, Hervás R, Carrión-Vázquez M, Laurents DV.

Arch Biochem Biophys. 2014 Sep 15;558:104-10. doi: 10.1016/j.abb.2014.06.025. Epub 2014 Jul 5.

PMID:
25009140
16.

Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.

Takeuchi T, Popiel HA, Futaki S, Wada K, Nagai Y.

Curr Med Chem. 2014;21(23):2575-82. Review.

PMID:
24533807
17.

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.

Herbst M, Wanker EE.

Curr Pharm Des. 2006;12(20):2543-55. Review.

PMID:
16842177
18.

Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.

Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T.

J Biol Chem. 2008 Sep 19;283(38):26188-97. doi: 10.1074/jbc.M710521200. Epub 2008 Jul 16.

19.

Structure-activity relationship study on polyglutamine binding peptide QBP1.

Tomita K, Popiel HA, Nagai Y, Toda T, Yoshimitsu Y, Ohno H, Oishi S, Fujii N.

Bioorg Med Chem. 2009 Feb 1;17(3):1259-63. doi: 10.1016/j.bmc.2008.12.018. Epub 2008 Dec 24.

PMID:
19121945
20.

Monitoring polyglutamine toxicity in yeast.

Duennwald ML.

Methods. 2011 Mar;53(3):232-7. doi: 10.1016/j.ymeth.2010.12.001. Epub 2010 Dec 6.

PMID:
21144902

Supplemental Content

Support Center